Clinical Research Associates, Inc.

If you are a type I or type II diabetic, you may be eligible to participate in a Continuous Glucose Monitoring (CGM) study. The study is NOT intended to change your Diabetes treatment.  It is seeking to continue the development of an experimental CGM system.  You will be asked to wear a CGM for about 14 days with frequent self- glucose monitoring (supplies provided). The results of the CGM will later be compared to your self- glucose monitoring.

Click here to learn more.

Are you one of the many people who experience moderate to severe migraine headaches at least twice monthly?  If so, We are seeking people like you to participate in a research study for the treatment of migraine headaches.  Participants will help learn more about the safety and effectiveness of an investigational medication.

Click here to learn more.

Now Enrolling Volunteers. -sign up here for updates.

As the population becomes increasingly heavy, the prevalence of Type 2 diabetes is also increasing.  Obesity/over-weight is a risk factor for developing diabetes as well as hypertension, stroke, some cancers, sleep apnea and many other conditions. Excessive weight is preventable and treatable. Even a weight loss of only 5-10% is associated with positive health benefits. If you do not have your glucose well controlled and need to lose weight, now is the time to make some changes.

Click here to learn more.

If you are struggling with weight management or need to participate in a weight loss program, we are seeking individuals who are ready to make the change.  A change in lifestyle, exercise along with medication.  Our research study combines such.  The purpose of this research study is to compare the safety and effectiveness of a research medication (Long acting human hormone) compared to a placebo.  At the end of the treatment period, all participants will have the opportunity to receive active medication.  Compensation is available for up to $1980 for time and travel.

What is required?

1. Ability to attend monthly clinic visits
2. Willing to give yourself and injection
3. Lifestyle changes as needed (dietary and exercise counseling provided)

Who can participate?

1. 18 years of age and older
2. BMI > 27
3. Committed to lose weight

There are no costs or insurance required.  All related visits, study medications and procedures are free of charge.  For details call our office at 615-329-2222 or click on the link to complete a basic form.  There are no obligations and compensation is available.

Have you tried a GLP-1 medication for weight loss but had to stop because of side effects?

If nausea, vomiting, constipation, or diarrhea made you stop the medication, we’d like to hear from you.

We are currently exploring newer medication options that may help support your weight-loss goals with potentially fewer or more manageable side effects.

Upcoming Study! Get on the waiting list

About 10% of the US Adult population has Type 2 diabetes (T2D).  Since Ozempic (semagludtide) was FDA approved in 2017 for the treatment of such, GLP-1 drugs have been increasingly used for glucose control.  Ozempic has since been approved for heart and kidney disease and weight loss.  Wegovy (higher dose semaglutide) was approved for weight loss in 2021.   It is estimated that 6% - 12% of US adults are currently taking GLP1 medication with about 1.3% specifically using Ozempic.

If you have been taking Ozempic or Wegovy and have T2D, you are not alone.  Studies have suggested HbA1c can be further lowered with the combination of other medications.

Study participants are needed who are currently taking Ozempic or Wegovy and have been diagnosed with T2D. The purpose of the study is to evaluate the safety and tolerability of switching Ozempic alone to a combination of Ozempic with another medication. All study medication will be provided and there are no placebos.

What is required?

1. Ability to make 13 office visits
2. Wear a provided Continuous Glucose Monitor (CGM) for the duration of the study
3. Complete provided eye exam
4. Adhere to study requirements
5. Lifestyle changes as needed (counseling provided)

Who can participate?

1. 18 and older who are diagnosed with T2D
2. Currently taking Ozempic or Wegovy
3. Relatively healthy with stable medical and psychiatric conditions
4. Interested in a comprehensive program for improved weight and HbA1C
5. BMI > 25 and HbA1C 6.5- 10.5

Non-Erosive Gastroesophageal Reflux Disease (GERD) is a very common condition that develops when the contents of your stomach flow back into the esophagus and cause troublesome heartburn.  A diagnostic endoscopic examination can determine if there has been injury to the esophagus (called erosive esophagitis).

Despite the availability of prescription and over-the-counter medications, the management of heartburn can be a problem.  Daily medications can prevent future heartburn but may not relieve an ongoing active episode.

The purpose of this study is to determine the safety and efficacy of an investigational oral medication called vonoprazan in the treatment of heartburn when taken “as needed.”  Vonoprazan is approved by the FDA for the relief of heartburn associated with non-erosive GERD in adults when taken once daily for 4 weeks. This study is evaluating a different way of taking vonoprazan – taking it only when a heartburn episode happens (also called “as needed”). All participants who qualify for the study will receive active treatment for 4 weeks followed by 24 weeks of either active medication or placebo and one week follow-up.

What does the study involve?

All participants will read and sign an Inform Consent Form (ICF) and keep an electronic diary to record episodes of heartburn and use of rescue antacid.  If you qualify for the study, you will undergo a screening EGD. You may not need an EGD if you had one within 2 weeks of your screening visit.  If there are no injuries to your esophagus (Erosions) or other abnormalities, and if you meet other requirements for this study, you will be provided with study medication and continue keeping a diary.  There are up to 7 visits to our office and 6 phone calls. The study medication, laboratory and diagnostic testing and physical exams are at no charge. Compensation up to $1240